Mirtazapine and paroxetine: A drug-drug interaction study in healthy subjects

Human Psychopharmacology

Volumn 16, Issue 6, 2001, Pages 449-459

  Ruwe, F J L ^a   Smulders, R A ^b   Kleijn, H J ^c   Hartmans, H L A ^c   Sitsen, J M A ^a  

^a Clinical Development Department   (Netherlands)

^b Kendle ^*  (Netherlands)

^c U Gene Clinical Pharmacology Unit   (Netherlands)

Author keywords

Cytochrome P450; Drug drug interaction; Mirtazapine; Paroxetine; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; DRUG METABOLITE; MIRTAZAPINE; PAROXETINE;

ADULT; ADVERSE DRUG REACTION; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INTERACTION; DRUG METABOLISM; ENZYME INHIBITION; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOLOGIC TEST; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; STEADY STATE; TITRIMETRY; VERTIGO;

EID: 0034821035     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.318     Document Type: Article

References (29)

1. Computer-assisted telephone administration of a structured interview for obsessive-compulsive disorder
2. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat
3. The pharmacological profile of mirtazapine
4. The use of analogue scales in rating subjective feelings
5. The statistical evaluation of a three-period two-treatment crossover pharmacokinetic drug interaction study
6. In vitro and in vivo studies on the disposition of mirtazapine in humans
7. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
8. A review of the psychomotor effects of paroxetine
9. Mirtazapine as treatment for serotonin syndrome
10. Single dose human pharmacology of umespirone
11. Mirtazapine. A review of its use in major depression
12. A review of the metabolism and pharmacokinetics of paroxetine in man
13. The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly
14. Potential withdrawal syndrome associated with SSRI discontinuation
15. Anti-depressant withdrawal syndrome: Recognition, prevention and management
16. High performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma
17. Augmentation strategies in patients with refractory depression
18. Factor analysis of a sleep evaluation questionnaire
19. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations-a review
20. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens
21. Pharmacokinetics of dextromethorphan and metabolites in humans: Influence of cytochrome P450 2D6 phenotype and quinidine inhibition
22. Comparative behavioural toxicity of the selective serotonin reuptake inhibitors
23. Concomitant use of mirtazapine and cimetidine: A drug-drug interaction study in healthy male subjects
24. Pharmacokinetics of mirtazapine and lithium in healthy male subjects
25. The serotonin syndrome: Implicated drugs, pathophysiology and management
26. Selective serotonin reuptake inhibitors and CNS drug interactions: A critical review of the evidence
27. Clinical pharmacokinetics of mirtazapine
28. The effects of moclobemide on cognition
29. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder